クリプトコッカス症治療薬の世界市場

クリプトコッカス症治療薬の世界市場は2030年までに60億米ドルに達する見込み

2024年に49億米ドルと推定されるクリプトコッカス症治療薬の世界市場は、2024～2030年の分析期間にCAGR 3.7%で成長し、2030年には60億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるフルシトシン治療は、CAGR 4.1％を記録し、分析期間終了までに35億米ドルに達すると予想されます。アムホテリシンB治療セグメントの成長率は、分析期間中CAGR 3.4％と推定されます。

米国市場は13億米ドルと推定、中国はCAGR6.8％で成長予測

米国のクリプトコッカス症治療薬市場は2024年に13億米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGR6.8％を引きずる形で、2030年までに12億米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.4%と2.8%と予測されています。欧州では、ドイツがCAGR 2.1%で成長すると予測されています。

世界のクリプトコッカス症治療薬市場- 主要動向と市場促進要因まとめ

なぜクリプトコッカス症は免疫不全集団で懸念が高まっているのか？

クリプトコッカス症は、クリプトコッカス属によって引き起こされる致死性の真菌感染症で、主にHIV/AIDS患者、臓器移植患者、化学療法を受けている患者などの免疫不全者が罹患します。この疾患は、中枢神経系の重篤な感染症であるクリプトコッカス髄膜炎として現れ、放置すると神経障害を引き起こし、死亡率が高くなります。HIVや積極的な治療を必要とする悪性腫瘍を含む免疫抑制状態の蔓延が、クリプトコッカス症の世界の発生率の上昇に寄与しています。サハラ以南のアフリカが最も高い疾病負担を負っており、クリプトコッカス髄膜炎はHIV陽性者の主要な死因のひとつです。抗レトロウイルス療法（ART）の開発にもかかわらず、発展途上国ではHIVの診断が遅く、抗真菌治療へのアクセスが限られているため、効果的なクリプトコッカス症治療薬の必要性が続いています。

現在の治療レジメンでは、アムホテリシンB、フルシトシン、フルコナゾールなどの抗真菌薬を組み合わせて使用しています。しかし、高い薬物毒性、治療期間の長期化、脳脊髄液（CSF）中への薬物浸透性の低さなどの限界が、新規治療薬の研究に拍車をかけています。さらに、抗真菌剤耐性菌の増加や、資源が限られた環境における標準化された治療プロトコルの欠如が、疾患管理を複雑にしています。クリプトコッカス症治療薬の世界市場では、製薬会社や研究機関がより強力で毒性が低く、入手しやすい抗真菌治療薬の開発に注力しており、注目度が高まっています。クリプトコッカス症は、特にHIV感染者の多い地域において、世界の健康上の重要な課題をもたらし続けているため、治療オプションの進歩や世界ヘルスへの取り組みの強化は、患者の転帰を改善する上で不可欠です。

クリプトコッカス症に対する新たな治療アプローチとは？

より効果的なクリプトコッカス症治療の必要性から、抗真菌薬開発における技術革新が推進され、有効性の向上、毒性の軽減、入手のしやすさなどに重点が置かれています。最も重要な進歩のひとつは、アムホテリシンBをリポソームアムホテリシンB（L-AmB）などの脂質ベース製剤やナノ粒子製剤に再製剤化したことです。これらの製剤は、従来のアムホテリシンB療法の大きな制限であった腎毒性を最小限に抑えながら、ドラッグデリバリーを向上させる。さらに、イサブコナゾールやポサコナゾールのような新世代のアゾール系抗真菌薬は、従来のフルコナゾール療法と比較して、患者の忍容性や治療成功率の改善において有望視されています。これらの新しいアゾール系抗真菌薬は、より広範な抗真菌活性と優れた薬物動態学的特性を示し、クリプトコッカス症管理における魅力的な選択肢となっています。

もう1つの有望な研究分野は抗真菌薬の併用療法であり、治療効果を高めると同時に耐性リスクを軽減することを目的としています。フルシトシンとアムホテリシンBの併用は生存率を向上させることが示されているが、世界の多くの地域でその利用可能性は依然として限られています。薬剤の再利用の進歩も治療の選択肢を広げており、セルトラリン（抗うつ薬）やタモキシフェン（乳がん治療薬）といった既存の薬剤がクリプトコッカス種に対する抗真菌効果を示しています。さらに、真菌感染に対する宿主の免疫反応を高めるために、モノクローナル抗体やサイトカインベースの治療を含む免疫療法のアプローチも研究されています。抗真菌薬感受性検査や個別化治療レジメンの改善とともに、これらの新たな戦略は、より効果的で安全な治療選択肢を患者に提供することで、クリプトコッカス症治療薬の展望を再構築しようとしています。

市場動向と規制の枠組みは医薬品開発にどのような影響を与えているか？

世界のクリプトコッカス症治療薬市場は、侵襲性真菌感染症の負担増とより効率的な治療プロトコルの必要性により、研究開発への投資が増加しています。製薬会社やバイオテクノロジー企業は次世代抗真菌薬の開発を優先しており、現在いくつかの新薬候補が前臨床試験や臨床試験の段階にあります。GAFFI（Global Action Fund for Fungal Infections）やユニタイド（Unitaid）が資金提供する先進HIV感染症イニシアチブ（Advanced HIV Disease Initiative）など、政府や非営利のイニシアチブが導入されたことで、中低所得国における必須抗真菌薬へのアクセスを改善する取り組みがさらに加速しています。これらのイニシアチブは、研究への資金提供、医薬品アクセスプログラムの拡大、クリプトコッカス感染症の診断改善を支援することで、治療ギャップを埋める一助となっています。

米国食品医薬品局（FDA）、欧州医薬品庁（EMA）、世界保健機関（WHO）は、より安全で効果的な抗真菌薬開発の重要性を強調しています。クリプトコッカス症治療薬に対する優先審査や希少疾病用医薬品の指定は、医薬品メーカーに臨床開発のスケジュールを早めるインセンティブを与えています。さらに、製薬会社、学術機関、国際保健機関の協力により、抗真菌剤研究の革新が促進され、高負担地域における手頃な価格と入手しやすさに焦点が当てられています。このような治療法の進歩にもかかわらず、治療費の高騰、必要な抗真菌薬の入手制限、新興市場における規制のボトルネックといった課題が、新しい治療法の普及を妨げています。政策改革、資金拡大、国際協力を通じてこれらの課題に対処することは、治療へのアクセスを向上させ、クリプトコッカス症に関連する死亡率を減少させる上で極めて重要です。

クリプトコッカス症治療薬市場の成長の原動力は？

クリプトコッカス症治療薬市場の成長は、抗真菌薬製剤の進歩、研究開発への投資の増加、免疫不全集団における疾患有病率の上昇など、いくつかの要因によって牽引されています。アムホテリシンBの脂質ベース製剤やナノ粒子製剤へのシフトは、有効性を維持しながら毒性を低減することで治療成績を大幅に改善しています。さらに、次世代アゾール系抗真菌薬と新規併用療法の開発により、クリプトコッカス症管理における既存の限界に対処しつつあります。また、迅速な分子診断やバイオマーカーに基づく検出システムの使用が増加しているため、疾患の早期発見が強化され、タイムリーな治療介入や生存率の向上につながっています。

病院、専門クリニック、学術研究機関では、クリプトコッカス症治療を感染症管理プログラムに組み込むケースが増えており、最終用途の拡大も大きな推進力となっています。遠隔診断と治療指導を提供するデジタルヘルスソリューションと遠隔医療プラットフォームの役割が拡大していることが、特に資源が乏しい地域での市場成長をさらに促進しています。さらに、製薬会社は世界の保健機関と戦略的パートナーシップを結び、流行地域における抗真菌薬へのアクセスを拡大しており、商業的成長と市場浸透を促進しています。侵襲性真菌感染症に対する医療従事者の意識の高まりは、抗真菌薬開発への資金提供の増加と相まって、今後数年間のクリプトコッカス症治療薬市場の成長を維持すると予想されます。革新的な治療アプローチが続々と登場する中、患者の予後改善と世界の医療格差への対応に重点を置く同市場は、今後大きく拡大するものと思われます。

セグメント

治療タイプ（フルシトシン治療薬、アムホテリシンB治療薬、フルコナゾール治療薬、その他の治療タイプ）、投与経路（経口投与、静脈内投与、吸入投与）、薬剤タイプ（先発医薬品、後発医薬品）、流通チャネル（病院薬局流通チャネル、小売薬局流通チャネル、オンライン薬局流通チャネル）

調査対象企業の例

• Abbott Laboratories
• Astellas Pharma Inc.
• Bausch Health Companies Inc.
• Bristol-Myers Squibb Company
• Eisai Co., Ltd.
• Flynn Pharma Ltd.
• Glenmark Pharmaceuticals
• Janssen Biotech Inc.
• Meda Consumer Healthcare Inc.
• Merck & Co., Inc.
• Neurim Pharmaceuticals Ltd.
• Novartis AG
• NuCare Pharmaceuticals, Inc.
• Pernix Therapeutics Holdings, Inc.
• Pfizer Inc.
• Sanofi
• Sigmapharm Laboratories LLC
• Sun Pharmaceutical Industries Ltd.
• Valeant Pharmaceuticals Inc.
• Viamet Pharmaceuticals Inc.

AIインテグレーション

検証された専門家のコンテンツとAIツールにより、市場情報と競合情報を変革します。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Cryptococcosis Therapeutics Market to Reach US$6.0 Billion by 2030

The global market for Cryptococcosis Therapeutics estimated at US$4.9 Billion in the year 2024, is expected to reach US$6.0 Billion by 2030, growing at a CAGR of 3.7% over the analysis period 2024-2030. Flucytosine Treatment, one of the segments analyzed in the report, is expected to record a 4.1% CAGR and reach US$3.5 Billion by the end of the analysis period. Growth in the Amphotericin B Treatment segment is estimated at 3.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.3 Billion While China is Forecast to Grow at 6.8% CAGR

The Cryptococcosis Therapeutics market in the U.S. is estimated at US$1.3 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.2 Billion by the year 2030 trailing a CAGR of 6.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.4% and 2.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.1% CAGR.

Global Cryptococcosis Therapeutics Market - Key Trends & Growth Drivers Summarized

Why Is Cryptococcosis a Growing Concern in Immunocompromised Populations?

Cryptococcosis, a potentially fatal fungal infection caused by Cryptococcus species, primarily affects immunocompromised individuals, including those with HIV/AIDS, organ transplant recipients, and patients undergoing chemotherapy. The disease manifests as cryptococcal meningitis, a severe infection of the central nervous system, which can lead to neurological damage and high mortality rates if left untreated. The increasing prevalence of immunosuppressive conditions, including HIV and malignancies requiring aggressive treatments, has contributed to the rising incidence of cryptococcosis worldwide. Sub-Saharan Africa bears the highest disease burden, with cryptococcal meningitis being one of the leading causes of death in HIV-positive individuals. Despite the development of antiretroviral therapy (ART), late-stage HIV diagnoses and limited access to antifungal treatments in developing countries continue to drive the need for effective cryptococcosis therapeutics.

Current treatment regimens involve a combination of antifungal agents, including amphotericin B, flucytosine, and fluconazole. However, limitations such as high drug toxicity, prolonged treatment durations, and poor drug penetration in cerebrospinal fluid (CSF) have spurred research into novel therapeutics. Additionally, the rise of antifungal resistance and the lack of standardized treatment protocols in resource-limited settings have complicated disease management. The global market for cryptococcosis therapeutics is witnessing increased attention from pharmaceutical companies and research organizations as they focus on developing more potent, less toxic, and easily accessible antifungal treatments. As cryptococcosis continues to pose a significant global health challenge, particularly in regions with a high HIV burden, advancements in therapeutic options and increased global health initiatives are essential in improving patient outcomes.

What Are the Emerging Therapeutic Approaches for Cryptococcosis?

The need for more effective cryptococcosis treatments has driven innovations in antifungal drug development, focusing on improved efficacy, reduced toxicity, and greater accessibility. One of the most significant advancements is the reformulation of amphotericin B into lipid-based and nanoparticle formulations, such as liposomal amphotericin B (L-AmB). These formulations enhance drug delivery while minimizing nephrotoxicity, a major limitation of conventional amphotericin B therapy. Additionally, new-generation azole antifungals, such as isavuconazole and posaconazole, have shown promise in improving patient tolerance and treatment success rates compared to traditional fluconazole therapy. These newer azoles exhibit broader antifungal activity and better pharmacokinetic properties, making them attractive alternatives in cryptococcosis management.

Another promising area of research is combination antifungal therapy, which aims to enhance treatment efficacy while reducing the risk of resistance. The combination of flucytosine with amphotericin B has been shown to improve survival rates, but its availability remains limited in many parts of the world. Advances in drug repurposing are also expanding therapeutic options, with existing drugs such as sertraline (an antidepressant) and tamoxifen (a breast cancer medication) demonstrating antifungal properties against Cryptococcus species. Moreover, immunotherapy approaches, including monoclonal antibodies and cytokine-based treatments, are being explored to enhance host immune responses against fungal infections. These novel strategies, alongside improvements in antifungal susceptibility testing and personalized treatment regimens, are poised to reshape the cryptococcosis therapeutics landscape, providing patients with more effective and safer treatment options.

How Are Market Trends and Regulatory Frameworks Influencing Drug Development?

The global cryptococcosis therapeutics market is witnessing increased investment in research and development, driven by the rising burden of invasive fungal infections and the need for more efficient treatment protocols. Pharmaceutical companies and biotech firms are prioritizing the development of next-generation antifungal agents, with several new drug candidates currently in preclinical and clinical trial stages. The introduction of government and non-profit initiatives, such as the Global Action Fund for Fungal Infections (GAFFI) and the Unitaid-funded Advanced HIV Disease Initiative, has further accelerated efforts to improve access to essential antifungal medicines in low- and middle-income countries. These initiatives are helping bridge treatment gaps by funding research, expanding drug access programs, and supporting diagnostic improvements for cryptococcal infections.

Regulatory frameworks are also shaping the cryptococcosis therapeutics market, with the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and World Health Organization (WHO) emphasizing the importance of developing safer and more effective antifungal treatments. Priority review and orphan drug designations for cryptococcosis therapeutics have incentivized drug manufacturers to accelerate clinical development timelines. Additionally, collaborative efforts between pharmaceutical companies, academic institutions, and global health organizations are fostering innovation in antifungal research, with a focus on affordability and accessibility in high-burden regions. Despite these advancements, challenges such as high treatment costs, limited availability of essential antifungal drugs, and regulatory bottlenecks in emerging markets continue to hinder widespread adoption of newer therapies. Addressing these challenges through policy reforms, expanded funding, and international cooperation will be crucial in enhancing treatment accessibility and reducing cryptococcosis-related mortality.

What Is Driving the Growth of the Cryptococcosis Therapeutics Market?

The growth in the cryptococcosis therapeutics market is driven by several factors, including advancements in antifungal drug formulations, increasing investments in research and development, and rising disease prevalence among immunocompromised populations. The shift toward lipid-based and nanoparticle formulations of amphotericin B has significantly improved treatment outcomes by reducing toxicity while maintaining efficacy. Additionally, the development of next-generation azole antifungals and novel combination therapies is addressing existing limitations in cryptococcosis management. The increasing use of rapid molecular diagnostics and biomarker-based detection systems is also enhancing early disease identification, leading to timely treatment interventions and improved survival rates.

End-use expansion is another major driver, with hospitals, specialty clinics, and academic research institutions increasingly incorporating cryptococcosis treatments into their infectious disease management programs. The growing role of digital health solutions and telemedicine platforms in providing remote diagnosis and treatment guidance is further facilitating market growth, particularly in resource-constrained regions. Additionally, pharmaceutical companies are forming strategic partnerships with global health organizations to expand access to antifungal medications in endemic areas, driving commercial growth and market penetration. The rising awareness about invasive fungal infections among healthcare professionals, coupled with increased funding for antifungal drug development, is expected to sustain the growth of the cryptococcosis therapeutics market in the coming years. As innovative treatment approaches continue to emerge, the market is poised for significant expansion, with a strong focus on improving patient outcomes and addressing global health disparities.

SCOPE OF STUDY:

The report analyzes the Cryptococcosis Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Treatment Type (Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment, Other Treatment Types); Administration Route (Oral Administration, Intravenous Administration, Inhalation Administration); Drug Type (Branded Drugs, Generic Drugs); Distribution Channel (Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

• Abbott Laboratories
• Astellas Pharma Inc.
• Bausch Health Companies Inc.
• Bristol-Myers Squibb Company
• Eisai Co., Ltd.
• Flynn Pharma Ltd.
• Glenmark Pharmaceuticals
• Janssen Biotech Inc.
• Meda Consumer Healthcare Inc.
• Merck & Co., Inc.
• Neurim Pharmaceuticals Ltd.
• Novartis AG
• NuCare Pharmaceuticals, Inc.
• Pernix Therapeutics Holdings, Inc.
• Pfizer Inc.
• Sanofi
• Sigmapharm Laboratories LLC
• Sun Pharmaceutical Industries Ltd.
• Valeant Pharmaceuticals Inc.
• Viamet Pharmaceuticals Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Tariff Impact on Global Supply Chain Patterns
  • Cryptococcosis Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Global Burden of Opportunistic Fungal Infections Drives Demand for Cryptococcosis Therapeutics
  • Increased Prevalence of HIV/AIDS in Low- and Middle-Income Countries Expands Treatment Market for Cryptococcosis
  • WHO and CDC Recognition of Cryptococcus Infections as a Priority Fungal Pathogen Spurs R&D Funding
  • Lack of Vaccines and High Mortality Rates Highlight Urgent Need for Novel Antifungal Therapies
  • OEM Innovation in Amphotericin B Formulations and Lipid-Based Delivery Systems Improves Safety Profiles
  • Emergence of Resistance to First-Line Antifungals Strengthens the Business Case for New Drug Candidates
  • Increased Clinical Trials in Sub-Saharan Africa and Southeast Asia Expands Regional Access to Therapies
  • OEM Collaboration With Global Health Organizations Enhances Supply Chain and Access Programs
  • Orphan Drug Designation and Fast Track Approvals Accelerate Time-to-Market for Novel Antifungal Agents
  • Post-COVID Focus on Immunocompromised Populations Throws Spotlight on Fungal Infections
  • Expansion of Diagnostic Capabilities in LMICs Fuels Early Detection and Treatment Demand
  • Investment in Antifungal Drug Discovery Platforms Accelerates Development of Targeted Cryptococcus Therapies
  • Limited Competition in Niche Fungal Therapeutics Market Creates Attractive Opportunity for Biotech Startups
  • Rising Awareness Among Healthcare Providers Strengthens Early Diagnosis and Treatment Outcomes
  • OEM Focus on Combination Therapies Supports Broader Coverage and Resistance Management
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Cryptococcosis Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Cryptococcosis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Cryptococcosis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Flucytosine Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Flucytosine Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Flucytosine Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Amphotericin B Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Amphotericin B Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Amphotericin B Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Fluconazole Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Fluconazole Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Fluconazole Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Other Treatment Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Hospital Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Hospital Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Hospital Pharmacies Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Retail Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Retail Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Retail Pharmacies Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Online Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Online Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Online Pharmacies Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Oral Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Intravenous Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Intravenous Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Intravenous Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Inhalation Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Inhalation Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Inhalation Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Branded Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Branded Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Branded Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Generic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Generic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Generic Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Cryptococcosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 41: USA Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Treatment Type - Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Cryptococcosis Therapeutics by Treatment Type - Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: USA 15-Year Perspective for Cryptococcosis Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 44: USA Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Cryptococcosis Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: USA 15-Year Perspective for Cryptococcosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 47: USA Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Administration Route - Oral Administration, Intravenous Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: USA Historic Review for Cryptococcosis Therapeutics by Administration Route - Oral Administration, Intravenous Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: USA 15-Year Perspective for Cryptococcosis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Intravenous Administration and Inhalation Administration for the Years 2015, 2025 & 2030
  • TABLE 50: USA Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: USA Historic Review for Cryptococcosis Therapeutics by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: USA 15-Year Perspective for Cryptococcosis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 53: Canada Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Treatment Type - Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Canada Historic Review for Cryptococcosis Therapeutics by Treatment Type - Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: Canada 15-Year Perspective for Cryptococcosis Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 56: Canada Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Canada Historic Review for Cryptococcosis Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: Canada 15-Year Perspective for Cryptococcosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 59: Canada Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Administration Route - Oral Administration, Intravenous Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Canada Historic Review for Cryptococcosis Therapeutics by Administration Route - Oral Administration, Intravenous Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: Canada 15-Year Perspective for Cryptococcosis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Intravenous Administration and Inhalation Administration for the Years 2015, 2025 & 2030
  • TABLE 62: Canada Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Canada Historic Review for Cryptococcosis Therapeutics by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: Canada 15-Year Perspective for Cryptococcosis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
• JAPAN
  • Cryptococcosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 65: Japan Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Treatment Type - Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Japan Historic Review for Cryptococcosis Therapeutics by Treatment Type - Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: Japan 15-Year Perspective for Cryptococcosis Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 68: Japan Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Japan Historic Review for Cryptococcosis Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: Japan 15-Year Perspective for Cryptococcosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 71: Japan Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Administration Route - Oral Administration, Intravenous Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Japan Historic Review for Cryptococcosis Therapeutics by Administration Route - Oral Administration, Intravenous Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: Japan 15-Year Perspective for Cryptococcosis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Intravenous Administration and Inhalation Administration for the Years 2015, 2025 & 2030
  • TABLE 74: Japan Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Japan Historic Review for Cryptococcosis Therapeutics by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: Japan 15-Year Perspective for Cryptococcosis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
• CHINA
  • Cryptococcosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 77: China Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Treatment Type - Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: China Historic Review for Cryptococcosis Therapeutics by Treatment Type - Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: China 15-Year Perspective for Cryptococcosis Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 80: China Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: China Historic Review for Cryptococcosis Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: China 15-Year Perspective for Cryptococcosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 83: China Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Administration Route - Oral Administration, Intravenous Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: China Historic Review for Cryptococcosis Therapeutics by Administration Route - Oral Administration, Intravenous Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: China 15-Year Perspective for Cryptococcosis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Intravenous Administration and Inhalation Administration for the Years 2015, 2025 & 2030
  • TABLE 86: China Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: China Historic Review for Cryptococcosis Therapeutics by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: China 15-Year Perspective for Cryptococcosis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
• EUROPE
  • Cryptococcosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 89: Europe Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 90: Europe Historic Review for Cryptococcosis Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: Europe 15-Year Perspective for Cryptococcosis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 92: Europe Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Treatment Type - Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Europe Historic Review for Cryptococcosis Therapeutics by Treatment Type - Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: Europe 15-Year Perspective for Cryptococcosis Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 95: Europe Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Europe Historic Review for Cryptococcosis Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: Europe 15-Year Perspective for Cryptococcosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 98: Europe Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Administration Route - Oral Administration, Intravenous Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Europe Historic Review for Cryptococcosis Therapeutics by Administration Route - Oral Administration, Intravenous Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Europe 15-Year Perspective for Cryptococcosis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Intravenous Administration and Inhalation Administration for the Years 2015, 2025 & 2030
  • TABLE 101: Europe Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Europe Historic Review for Cryptococcosis Therapeutics by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: Europe 15-Year Perspective for Cryptococcosis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
• FRANCE
  • Cryptococcosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 104: France Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Treatment Type - Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: France Historic Review for Cryptococcosis Therapeutics by Treatment Type - Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: France 15-Year Perspective for Cryptococcosis Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 107: France Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: France Historic Review for Cryptococcosis Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: France 15-Year Perspective for Cryptococcosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 110: France Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Administration Route - Oral Administration, Intravenous Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: France Historic Review for Cryptococcosis Therapeutics by Administration Route - Oral Administration, Intravenous Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: France 15-Year Perspective for Cryptococcosis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Intravenous Administration and Inhalation Administration for the Years 2015, 2025 & 2030
  • TABLE 113: France Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: France Historic Review for Cryptococcosis Therapeutics by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: France 15-Year Perspective for Cryptococcosis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
• GERMANY
  • Cryptococcosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 116: Germany Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Treatment Type - Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Germany Historic Review for Cryptococcosis Therapeutics by Treatment Type - Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: Germany 15-Year Perspective for Cryptococcosis Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 119: Germany Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Germany Historic Review for Cryptococcosis Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: Germany 15-Year Perspective for Cryptococcosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 122: Germany Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Administration Route - Oral Administration, Intravenous Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Germany Historic Review for Cryptococcosis Therapeutics by Administration Route - Oral Administration, Intravenous Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: Germany 15-Year Perspective for Cryptococcosis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Intravenous Administration and Inhalation Administration for the Years 2015, 2025 & 2030
  • TABLE 125: Germany Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Germany Historic Review for Cryptococcosis Therapeutics by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: Germany 15-Year Perspective for Cryptococcosis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 128: Italy Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Treatment Type - Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Italy Historic Review for Cryptococcosis Therapeutics by Treatment Type - Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: Italy 15-Year Perspective for Cryptococcosis Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 131: Italy Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Italy Historic Review for Cryptococcosis Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Italy 15-Year Perspective for Cryptococcosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 134: Italy Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Administration Route - Oral Administration, Intravenous Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Italy Historic Review for Cryptococcosis Therapeutics by Administration Route - Oral Administration, Intravenous Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Italy 15-Year Perspective for Cryptococcosis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Intravenous Administration and Inhalation Administration for the Years 2015, 2025 & 2030
  • TABLE 137: Italy Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Italy Historic Review for Cryptococcosis Therapeutics by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Italy 15-Year Perspective for Cryptococcosis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Cryptococcosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 140: UK Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Treatment Type - Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: UK Historic Review for Cryptococcosis Therapeutics by Treatment Type - Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: UK 15-Year Perspective for Cryptococcosis Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 143: UK Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: UK Historic Review for Cryptococcosis Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: UK 15-Year Perspective for Cryptococcosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 146: UK Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Administration Route - Oral Administration, Intravenous Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: UK Historic Review for Cryptococcosis Therapeutics by Administration Route - Oral Administration, Intravenous Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: UK 15-Year Perspective for Cryptococcosis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Intravenous Administration and Inhalation Administration for the Years 2015, 2025 & 2030
  • TABLE 149: UK Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: UK Historic Review for Cryptococcosis Therapeutics by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: UK 15-Year Perspective for Cryptococcosis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 152: Spain Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Treatment Type - Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Spain Historic Review for Cryptococcosis Therapeutics by Treatment Type - Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Spain 15-Year Perspective for Cryptococcosis Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 155: Spain Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Spain Historic Review for Cryptococcosis Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Spain 15-Year Perspective for Cryptococcosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 158: Spain Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Administration Route - Oral Administration, Intravenous Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Spain Historic Review for Cryptococcosis Therapeutics by Administration Route - Oral Administration, Intravenous Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Spain 15-Year Perspective for Cryptococcosis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Intravenous Administration and Inhalation Administration for the Years 2015, 2025 & 2030
  • TABLE 161: Spain Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Spain Historic Review for Cryptococcosis Therapeutics by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Spain 15-Year Perspective for Cryptococcosis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 164: Russia Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Treatment Type - Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Russia Historic Review for Cryptococcosis Therapeutics by Treatment Type - Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Russia 15-Year Perspective for Cryptococcosis Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 167: Russia Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Russia Historic Review for Cryptococcosis Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: Russia 15-Year Perspective for Cryptococcosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 170: Russia Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Administration Route - Oral Administration, Intravenous Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Russia Historic Review for Cryptococcosis Therapeutics by Administration Route - Oral Administration, Intravenous Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: Russia 15-Year Perspective for Cryptococcosis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Intravenous Administration and Inhalation Administration for the Years 2015, 2025 & 2030
  • TABLE 173: Russia Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Russia Historic Review for Cryptococcosis Therapeutics by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: Russia 15-Year Perspective for Cryptococcosis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 176: Rest of Europe Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Treatment Type - Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Rest of Europe Historic Review for Cryptococcosis Therapeutics by Treatment Type - Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: Rest of Europe 15-Year Perspective for Cryptococcosis Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 179: Rest of Europe Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Rest of Europe Historic Review for Cryptococcosis Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: Rest of Europe 15-Year Perspective for Cryptococcosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 182: Rest of Europe Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Administration Route - Oral Administration, Intravenous Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Rest of Europe Historic Review for Cryptococcosis Therapeutics by Administration Route - Oral Administration, Intravenous Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: Rest of Europe 15-Year Perspective for Cryptococcosis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Intravenous Administration and Inhalation Administration for the Years 2015, 2025 & 2030
  • TABLE 185: Rest of Europe Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Rest of Europe Historic Review for Cryptococcosis Therapeutics by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: Rest of Europe 15-Year Perspective for Cryptococcosis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Cryptococcosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 188: Asia-Pacific Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 189: Asia-Pacific Historic Review for Cryptococcosis Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: Asia-Pacific 15-Year Perspective for Cryptococcosis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 191: Asia-Pacific Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Treatment Type - Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Asia-Pacific Historic Review for Cryptococcosis Therapeutics by Treatment Type - Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Asia-Pacific 15-Year Perspective for Cryptococcosis Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 194: Asia-Pacific Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Asia-Pacific Historic Review for Cryptococcosis Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Asia-Pacific 15-Year Perspective for Cryptococcosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 197: Asia-Pacific Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Administration Route - Oral Administration, Intravenous Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Asia-Pacific Historic Review for Cryptococcosis Therapeutics by Administration Route - Oral Administration, Intravenous Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Asia-Pacific 15-Year Perspective for Cryptococcosis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Intravenous Administration and Inhalation Administration for the Years 2015, 2025 & 2030
  • TABLE 200: Asia-Pacific Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Asia-Pacific Historic Review for Cryptococcosis Therapeutics by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Asia-Pacific 15-Year Perspective for Cryptococcosis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Cryptococcosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 203: Australia Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Treatment Type - Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Australia Historic Review for Cryptococcosis Therapeutics by Treatment Type - Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Australia 15-Year Perspective for Cryptococcosis Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 206: Australia Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Australia Historic Review for Cryptococcosis Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Australia 15-Year Perspective for Cryptococcosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 209: Australia Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Administration Route - Oral Administration, Intravenous Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Australia Historic Review for Cryptococcosis Therapeutics by Administration Route - Oral Administration, Intravenous Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Australia 15-Year Perspective for Cryptococcosis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Intravenous Administration and Inhalation Administration for the Years 2015, 2025 & 2030
  • TABLE 212: Australia Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Australia Historic Review for Cryptococcosis Therapeutics by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Australia 15-Year Perspective for Cryptococcosis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
• INDIA
  • Cryptococcosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 215: India Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Treatment Type - Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: India Historic Review for Cryptococcosis Therapeutics by Treatment Type - Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: India 15-Year Perspective for Cryptococcosis Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 218: India Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: India Historic Review for Cryptococcosis Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: India 15-Year Perspective for Cryptococcosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 221: India Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Administration Route - Oral Administration, Intravenous Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: India Historic Review for Cryptococcosis Therapeutics by Administration Route - Oral Administration, Intravenous Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: India 15-Year Perspective for Cryptococcosis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Intravenous Administration and Inhalation Administration for the Years 2015, 2025 & 2030
  • TABLE 224: India Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: India Historic Review for Cryptococcosis Therapeutics by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: India 15-Year Perspective for Cryptococcosis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 227: South Korea Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Treatment Type - Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: South Korea Historic Review for Cryptococcosis Therapeutics by Treatment Type - Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: South Korea 15-Year Perspective for Cryptococcosis Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 230: South Korea Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: South Korea Historic Review for Cryptococcosis Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: South Korea 15-Year Perspective for Cryptococcosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 233: South Korea Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Administration Route - Oral Administration, Intravenous Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: South Korea Historic Review for Cryptococcosis Therapeutics by Administration Route - Oral Administration, Intravenous Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: South Korea 15-Year Perspective for Cryptococcosis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Intravenous Administration and Inhalation Administration for the Years 2015, 2025 & 2030
  • TABLE 236: South Korea Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: South Korea Historic Review for Cryptococcosis Therapeutics by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: South Korea 15-Year Perspective for Cryptococcosis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 239: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Treatment Type - Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Asia-Pacific Historic Review for Cryptococcosis Therapeutics by Treatment Type - Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Rest of Asia-Pacific 15-Year Perspective for Cryptococcosis Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 242: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Asia-Pacific Historic Review for Cryptococcosis Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Rest of Asia-Pacific 15-Year Perspective for Cryptococcosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 245: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Administration Route - Oral Administration, Intravenous Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Rest of Asia-Pacific Historic Review for Cryptococcosis Therapeutics by Administration Route - Oral Administration, Intravenous Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Rest of Asia-Pacific 15-Year Perspective for Cryptococcosis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Intravenous Administration and Inhalation Administration for the Years 2015, 2025 & 2030
  • TABLE 248: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Rest of Asia-Pacific Historic Review for Cryptococcosis Therapeutics by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Rest of Asia-Pacific 15-Year Perspective for Cryptococcosis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Cryptococcosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 251: Latin America Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 252: Latin America Historic Review for Cryptococcosis Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Latin America 15-Year Perspective for Cryptococcosis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 254: Latin America Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Treatment Type - Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Latin America Historic Review for Cryptococcosis Therapeutics by Treatment Type - Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Latin America 15-Year Perspective for Cryptococcosis Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 257: Latin America Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Latin America Historic Review for Cryptococcosis Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Latin America 15-Year Perspective for Cryptococcosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 260: Latin America Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Administration Route - Oral Administration, Intravenous Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Latin America Historic Review for Cryptococcosis Therapeutics by Administration Route - Oral Administration, Intravenous Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Latin America 15-Year Perspective for Cryptococcosis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Intravenous Administration and Inhalation Administration for the Years 2015, 2025 & 2030
  • TABLE 263: Latin America Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Latin America Historic Review for Cryptococcosis Therapeutics by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Latin America 15-Year Perspective for Cryptococcosis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 266: Argentina Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Treatment Type - Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Argentina Historic Review for Cryptococcosis Therapeutics by Treatment Type - Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Argentina 15-Year Perspective for Cryptococcosis Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 269: Argentina Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Argentina Historic Review for Cryptococcosis Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Argentina 15-Year Perspective for Cryptococcosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 272: Argentina Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Administration Route - Oral Administration, Intravenous Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Argentina Historic Review for Cryptococcosis Therapeutics by Administration Route - Oral Administration, Intravenous Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Argentina 15-Year Perspective for Cryptococcosis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Intravenous Administration and Inhalation Administration for the Years 2015, 2025 & 2030
  • TABLE 275: Argentina Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Argentina Historic Review for Cryptococcosis Therapeutics by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Argentina 15-Year Perspective for Cryptococcosis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 278: Brazil Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Treatment Type - Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Brazil Historic Review for Cryptococcosis Therapeutics by Treatment Type - Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: Brazil 15-Year Perspective for Cryptococcosis Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 281: Brazil Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Brazil Historic Review for Cryptococcosis Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: Brazil 15-Year Perspective for Cryptococcosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 284: Brazil Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Administration Route - Oral Administration, Intravenous Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Brazil Historic Review for Cryptococcosis Therapeutics by Administration Route - Oral Administration, Intravenous Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: Brazil 15-Year Perspective for Cryptococcosis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Intravenous Administration and Inhalation Administration for the Years 2015, 2025 & 2030
  • TABLE 287: Brazil Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Brazil Historic Review for Cryptococcosis Therapeutics by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: Brazil 15-Year Perspective for Cryptococcosis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 290: Mexico Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Treatment Type - Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Mexico Historic Review for Cryptococcosis Therapeutics by Treatment Type - Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: Mexico 15-Year Perspective for Cryptococcosis Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 293: Mexico Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Mexico Historic Review for Cryptococcosis Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: Mexico 15-Year Perspective for Cryptococcosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 296: Mexico Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Administration Route - Oral Administration, Intravenous Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Mexico Historic Review for Cryptococcosis Therapeutics by Administration Route - Oral Administration, Intravenous Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: Mexico 15-Year Perspective for Cryptococcosis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Intravenous Administration and Inhalation Administration for the Years 2015, 2025 & 2030
  • TABLE 299: Mexico Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Mexico Historic Review for Cryptococcosis Therapeutics by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: Mexico 15-Year Perspective for Cryptococcosis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 302: Rest of Latin America Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Treatment Type - Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Rest of Latin America Historic Review for Cryptococcosis Therapeutics by Treatment Type - Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: Rest of Latin America 15-Year Perspective for Cryptococcosis Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 305: Rest of Latin America Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Rest of Latin America Historic Review for Cryptococcosis Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: Rest of Latin America 15-Year Perspective for Cryptococcosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 308: Rest of Latin America Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Administration Route - Oral Administration, Intravenous Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Rest of Latin America Historic Review for Cryptococcosis Therapeutics by Administration Route - Oral Administration, Intravenous Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 310: Rest of Latin America 15-Year Perspective for Cryptococcosis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Intravenous Administration and Inhalation Administration for the Years 2015, 2025 & 2030
  • TABLE 311: Rest of Latin America Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Rest of Latin America Historic Review for Cryptococcosis Therapeutics by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 313: Rest of Latin America 15-Year Perspective for Cryptococcosis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Cryptococcosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 314: Middle East Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 315: Middle East Historic Review for Cryptococcosis Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 316: Middle East 15-Year Perspective for Cryptococcosis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 317: Middle East Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Treatment Type - Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Middle East Historic Review for Cryptococcosis Therapeutics by Treatment Type - Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 319: Middle East 15-Year Perspective for Cryptococcosis Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 320: Middle East Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 321: Middle East Historic Review for Cryptococcosis Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 322: Middle East 15-Year Perspective for Cryptococcosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 323: Middle East Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Administration Route - Oral Administration, Intravenous Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 324: Middle East Historic Review for Cryptococcosis Therapeutics by Administration Route - Oral Administration, Intravenous Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 325: Middle East 15-Year Perspective for Cryptococcosis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Intravenous Administration and Inhalation Administration for the Years 2015, 2025 & 2030
  • TABLE 326: Middle East Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 327: Middle East Historic Review for Cryptococcosis Therapeutics by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 328: Middle East 15-Year Perspective for Cryptococcosis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 329: Iran Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Treatment Type - Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 330: Iran Historic Review for Cryptococcosis Therapeutics by Treatment Type - Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 331: Iran 15-Year Perspective for Cryptococcosis Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 332: Iran Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 333: Iran Historic Review for Cryptococcosis Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 334: Iran 15-Year Perspective for Cryptococcosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 335: Iran Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Administration Route - Oral Administration, Intravenous Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 336: Iran Historic Review for Cryptococcosis Therapeutics by Administration Route - Oral Administration, Intravenous Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 337: Iran 15-Year Perspective for Cryptococcosis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Intravenous Administration and Inhalation Administration for the Years 2015, 2025 & 2030
  • TABLE 338: Iran Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 339: Iran Historic Review for Cryptococcosis Therapeutics by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 340: Iran 15-Year Perspective for Cryptococcosis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 341: Israel Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Treatment Type - Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 342: Israel Historic Review for Cryptococcosis Therapeutics by Treatment Type - Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 343: Israel 15-Year Perspective for Cryptococcosis Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 344: Israel Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 345: Israel Historic Review for Cryptococcosis Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 346: Israel 15-Year Perspective for Cryptococcosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 347: Israel Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Administration Route - Oral Administration, Intravenous Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 348: Israel Historic Review for Cryptococcosis Therapeutics by Administration Route - Oral Administration, Intravenous Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 349: Israel 15-Year Perspective for Cryptococcosis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Intravenous Administration and Inhalation Administration for the Years 2015, 2025 & 2030
  • TABLE 350: Israel Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 351: Israel Historic Review for Cryptococcosis Therapeutics by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 352: Israel 15-Year Perspective for Cryptococcosis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 353: Saudi Arabia Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Treatment Type - Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 354: Saudi Arabia Historic Review for Cryptococcosis Therapeutics by Treatment Type - Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 355: Saudi Arabia 15-Year Perspective for Cryptococcosis Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 356: Saudi Arabia Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 357: Saudi Arabia Historic Review for Cryptococcosis Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 358: Saudi Arabia 15-Year Perspective for Cryptococcosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 359: Saudi Arabia Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Administration Route - Oral Administration, Intravenous Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 360: Saudi Arabia Historic Review for Cryptococcosis Therapeutics by Administration Route - Oral Administration, Intravenous Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 361: Saudi Arabia 15-Year Perspective for Cryptococcosis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Intravenous Administration and Inhalation Administration for the Years 2015, 2025 & 2030
  • TABLE 362: Saudi Arabia Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 363: Saudi Arabia Historic Review for Cryptococcosis Therapeutics by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 364: Saudi Arabia 15-Year Perspective for Cryptococcosis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 365: UAE Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Treatment Type - Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 366: UAE Historic Review for Cryptococcosis Therapeutics by Treatment Type - Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 367: UAE 15-Year Perspective for Cryptococcosis Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 368: UAE Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 369: UAE Historic Review for Cryptococcosis Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 370: UAE 15-Year Perspective for Cryptococcosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 371: UAE Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Administration Route - Oral Administration, Intravenous Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 372: UAE Historic Review for Cryptococcosis Therapeutics by Administration Route - Oral Administration, Intravenous Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 373: UAE 15-Year Perspective for Cryptococcosis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Intravenous Administration and Inhalation Administration for the Years 2015, 2025 & 2030
  • TABLE 374: UAE Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 375: UAE Historic Review for Cryptococcosis Therapeutics by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 376: UAE 15-Year Perspective for Cryptococcosis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 377: Rest of Middle East Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Treatment Type - Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 378: Rest of Middle East Historic Review for Cryptococcosis Therapeutics by Treatment Type - Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 379: Rest of Middle East 15-Year Perspective for Cryptococcosis Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 380: Rest of Middle East Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 381: Rest of Middle East Historic Review for Cryptococcosis Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 382: Rest of Middle East 15-Year Perspective for Cryptococcosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 383: Rest of Middle East Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Administration Route - Oral Administration, Intravenous Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 384: Rest of Middle East Historic Review for Cryptococcosis Therapeutics by Administration Route - Oral Administration, Intravenous Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 385: Rest of Middle East 15-Year Perspective for Cryptococcosis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Intravenous Administration and Inhalation Administration for the Years 2015, 2025 & 2030
  • TABLE 386: Rest of Middle East Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 387: Rest of Middle East Historic Review for Cryptococcosis Therapeutics by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 388: Rest of Middle East 15-Year Perspective for Cryptococcosis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
• AFRICA
  • Cryptococcosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 389: Africa Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Treatment Type - Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 390: Africa Historic Review for Cryptococcosis Therapeutics by Treatment Type - Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 391: Africa 15-Year Perspective for Cryptococcosis Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Flucytosine Treatment, Amphotericin B Treatment, Fluconazole Treatment and Other Treatment Types for the Years 2015, 2025 & 2030
  • TABLE 392: Africa Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 393: Africa Historic Review for Cryptococcosis Therapeutics by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 394: Africa 15-Year Perspective for Cryptococcosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 395: Africa Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Administration Route - Oral Administration, Intravenous Administration and Inhalation Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 396: Africa Historic Review for Cryptococcosis Therapeutics by Administration Route - Oral Administration, Intravenous Administration and Inhalation Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 397: Africa 15-Year Perspective for Cryptococcosis Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Intravenous Administration and Inhalation Administration for the Years 2015, 2025 & 2030
  • TABLE 398: Africa Recent Past, Current & Future Analysis for Cryptococcosis Therapeutics by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 399: Africa Historic Review for Cryptococcosis Therapeutics by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 400: Africa 15-Year Perspective for Cryptococcosis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030

IV. COMPETITION